| P50 | author | Christoph Bode | Q60457714 |
| | Dan Atar | Q65660970 |
| P2093 | author name string | André Stuerzenbecher | |
| | Freek W. A. Verheugt | |
| P2860 | cites work | Dual antiplatelet therapy and antithrombotic treatment in patients with acute coronary syndrome--does everyday medical practice reflects current recommendations? A pilot study | Q82421278 |
| | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial | Q84062702 |
| | Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, pla | Q84098449 |
| | Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51) | Q86859640 |
| | One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database | Q94681228 |
| | Are we mortgaging the medical profession? | Q95814757 |
| | ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) | Q22242892 |
| | Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial | Q28165358 |
| | Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators | Q28176380 |
| | Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 |
| | Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients | Q28190844 |
| | Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study | Q28192316 |
| | Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial | Q28193437 |
| | Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial | Q28193553 |
| | Warfarin, aspirin, or both after myocardial infarction | Q28193836 |
| | Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes | Q28213006 |
| | Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 |
| | Triggers, targets and treatments for thrombosis | Q33765444 |
| | Changes in clinical profile, treatment, and mortality in patients hospitalised for acute myocardial infarction between 1985 and 2008 | Q34071675 |
| | ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice g | Q34154695 |
| | ??? | Q22242895 |
| | Apixaban with antiplatelet therapy after acute coronary syndrome | Q34202772 |
| | Rivaroxaban in patients with a recent acute coronary syndrome | Q34231902 |
| | Update on acute coronary syndromes: the pathologists' view | Q34646452 |
| | 25 year trends in first time hospitalisation for acute myocardial infarction, subsequent short and long term mortality, and the prognostic impact of sex and comorbidity: a Danish nationwide cohort study | Q35696662 |
| | The pathogenesis of coronary artery disease and the acute coronary syndromes (1). | Q36728740 |
| | Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome | Q37012333 |
| | Thrombosis and acute coronary syndrome | Q37979021 |
| | Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis | Q39842429 |
| | Comparison of baseline characteristics, management and outcome of patients with non-ST-segment elevation acute coronary syndrome in versus not in clinical trials | Q42830364 |
| | Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes | Q43258808 |
| | The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). | Q43836940 |
| | Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Q45748252 |
| | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. | Q45962608 |
| | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. | Q45995789 |
| | Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. | Q46525958 |
| | Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 |
| | Trends in community mortality due to coronary heart disease. | Q50776382 |
| | One-year cardiovascular event rates in outpatients with atherothrombosis. | Q50801087 |
| | 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol | Q55056448 |
| | Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina | Q57200480 |
| | Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006 | Q57243464 |
| | Management of acute myocardial infarction in patients presenting with ST-segment elevation | Q61651499 |
| | Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group | Q72708506 |
| | Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators | Q73592736 |
| | Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation | Q78722335 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myocardial infarction | Q12152 |
| | anticoagulant | Q215118 |
| | acute coronary syndrome | Q266018 |
| | anticoagulation | Q63279445 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 353-63 | |
| P577 | publication date | 2014-08-01 | |
| P1433 | published in | Fundamental and Clinical Pharmacology | Q15760364 |
| P1476 | title | Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade | |
| P478 | volume | 28 | |